Ketorolac tromethamine is under clinical development by Neumentum and currently in Phase III for Post-Operative Pain. According to GlobalData, Phase III drugs for Post-Operative Pain have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Ketorolac tromethamine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ketorolac tromethamine overview
Ketorolac tromethamine (NTM-001) is under development for the treatment of post-operative pain. The drug candidate is an alcohol-free formulation non-steroidal anti-inflammatory drug ketorolac designed to provide 24 hours of continuous infusion. It is administered by intravenous route. It acts by targeting cyclooxygenase I (COX I) and cyclooxygenase II (COX II).
Neumentum is a non-opioid analgesic and neurology specialty pharmaceutical company. The company’s technology is transforming the way pain is managed without the risk of misuse, addiction or life-threatening side effects.
For a complete picture of Ketorolac tromethamine’s drug-specific PTSR and LoA scores, buy the report here.